Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.

Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S, Verma A, Ye BH, Janakiram M.

Blood. 2018 Aug 13. pii: blood-2018-01-824607. doi: 10.1182/blood-2018-01-824607. [Epub ahead of print]

PMID:
30104217
2.

Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant - a case series.

Adrianzen Herrera D, Ayyappan S, Jasra S, Kornblum N, Derman O, Shastri A, Mantzaris I, Verma A, Braunschweig I, Janakiram M.

Leuk Lymphoma. 2018 Jul 3:1-7. doi: 10.1080/10428194.2018.1474523. [Epub ahead of print]

PMID:
29969336
3.

Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy.

Ratner L, Waldmann TA, Janakiram M, Brammer JE.

N Engl J Med. 2018 May 17;378(20):1947-1948. doi: 10.1056/NEJMc1803181. No abstract available.

4.

Diagnostic challenges of adult T-cell leukemia/lymphoma in North America - a clinical, histological, and immunophenotypic correlation with a workflow proposal.

Licata MJ, Janakiram M, Tan S, Fang Y, Shah UA, Verma AK, Wang Y.

Leuk Lymphoma. 2018 May;59(5):1188-1194. doi: 10.1080/10428194.2017.1365862. Epub 2017 Aug 25.

PMID:
29504866
5.

Effect of Hepatitis B and C Infection on Recruitment for Cancer Clinical Trials.

Janakiram M, Jasra S, Aboulafia D.

J Clin Oncol. 2018 Apr 1;36(10):1047-1048. doi: 10.1200/JCO.2017.76.9307. Epub 2018 Jan 30. No abstract available.

PMID:
29381434
6.

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.

Cheng H, Borczuk A, Janakiram M, Ren X, Lin J, Assal A, Halmos B, Perez-Soler R, Zang X.

Clin Cancer Res. 2018 Apr 15;24(8):1954-1964. doi: 10.1158/1078-0432.CCR-17-2924. Epub 2018 Jan 26.

PMID:
29374053
7.

Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia.

Darbinyan K, Shastri A, Budhathoki A, Helbig D, Snyder R, Pradhan K, Saleh-Esa J, Kornblum NS, Binder AF, Goel S, Janakiram M, Derman O, Gritsman K, Steidl U, Braunschweig I, Verma A, Mantzaris I.

Blood Adv. 2017 Oct 26;1(24):2120-2123. doi: 10.1182/bloodadvances.2017007013. eCollection 2017 Nov 14.

8.

Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma.

Shastri A, Janakiram M, Mantzaris I, Yu Y, Londono JS, Verma AK, Barta SK.

Oncotarget. 2017 Jul 14;8(45):78410-78418. doi: 10.18632/oncotarget.19240. eCollection 2017 Oct 3.

9.

Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G-CSF in multiple myeloma: A pilot study.

Shastri A, Budhathoki A, Barta SK, Kornblum N, Derman O, Battini R, Raghupathy R, Verma AK, Frenette PS, Braunschweig I, Janakiram M.

Am J Hematol. 2017 Oct;92(10):1047-1051. doi: 10.1002/ajh.24843. Epub 2017 Jul 29.

PMID:
28675459
10.

Ibrutinib-induced severe liver injury.

Nandikolla AG, Derman O, Nautsch D, Liu Q, Massoumi H, Venugopal S, Braunschweig I, Janakiram M.

Clin Case Rep. 2017 Mar 15;5(6):735-738. doi: 10.1002/ccr3.881. eCollection 2017 Jun.

11.

Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.

Janakiram M, Verma A, Wang Y, Budhathoki A, Suarez Londono J, Murakhovskaya I, Braunschweig I, Minniti CP.

Leuk Lymphoma. 2018 Jan;59(1):241-244. doi: 10.1080/10428194.2017.1324158. Epub 2017 Jun 7. No abstract available.

PMID:
28587497
12.

An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.

McLemore LE, Janakiram M, Albanese J, Shapiro N, Lo Y, Zang X, Fineberg S.

Appl Immunohistochem Mol Morphol. 2017 Apr 18. doi: 10.1097/PAI.0000000000000485. [Epub ahead of print]

PMID:
28422766
13.

The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP, Zang X.

Immunol Rev. 2017 Mar;276(1):26-39. doi: 10.1111/imr.12521. Review.

14.

JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?

Liu KG, Verma A, Derman O, Kornblum N, Janakiram M, Braunschweig I, Battini R.

Biomark Res. 2016 Oct 19;4:19. eCollection 2016.

15.

HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.

Cheng H, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H, Chinai JM, Halmos B, Perez-Soler R, Zang X.

Clin Cancer Res. 2017 Feb 1;23(3):825-832. doi: 10.1158/1078-0432.CCR-15-3071. Epub 2016 Aug 23.

16.

Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies.

Janakiram M, Pareek V, Cheng H, Narasimhulu DM, Zang X.

Immunotherapy. 2016 Jun;8(7):809-19. doi: 10.2217/imt-2016-0001. Review.

17.

Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy.

Zell M, Assal A, Derman O, Kornblum N, Battini R, Wang Y, Narasimhulu DM, Mantzaris I, Shastri A, Verma A, Ye H, Braunschweig I, Janakiram M.

Oncotarget. 2016 Aug 9;7(32):51981-51990. doi: 10.18632/oncotarget.10223.

18.

Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans.

Mantzaris I, Yu Y, Msaouel P, Lam AP, Janakiram M, Friedman EW, Steidl U, Verma AK.

Oncotarget. 2016 Oct 18;7(42):67948-67955. doi: 10.18632/oncotarget.8996.

19.

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.

Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A.

Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. No abstract available.

PMID:
27125205
20.

Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor.

Assal A, Dong B, Khan H, Medavarapu R, Shastri A, Pradhan K, Friedman E, Mantzaris I, Janakiram M, Battini R, Kornblum N, Yu Y, Verma A, Braunschweig I, Derman O.

Leuk Lymphoma. 2016 Oct;57(10):2452-5. doi: 10.3109/10428194.2016.1142087. Epub 2016 Feb 17. No abstract available.

PMID:
26886689
21.

Lenalidomide in the treatment of Rosai Dorfman disease--a first in use report.

Rubinstein M, Assal A, Scherba M, Elman J, White R, Verma A, Strakhan M, Mohammadi F, Janakiram M.

Am J Hematol. 2016 Feb;91(2):E1. doi: 10.1002/ajh.24225. No abstract available.

22.

HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families.

Janakiram M, Chinai JM, Zhao A, Sparano JA, Zang X.

Oncoimmunology. 2015 Apr 14;4(8):e1026534. eCollection 2015 Aug.

23.

New immunotherapies targeting the PD-1 pathway.

Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X.

Trends Pharmacol Sci. 2015 Sep;36(9):587-95. doi: 10.1016/j.tips.2015.06.005. Epub 2015 Jul 7. Review.

24.

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.

Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medavarapu R, Castano E, Jeon H, Ohaegbulam KC, Zhao R, Zhao A, Almo SC, Sparano JA, Zang X.

Clin Cancer Res. 2015 May 15;21(10):2359-66. doi: 10.1158/1078-0432.CCR-14-1495. Epub 2014 Dec 30.

25.

Structure and cancer immunotherapy of the B7 family member B7x.

Jeon H, Vigdorovich V, Garrett-Thomson SC, Janakiram M, Ramagopal UA, Abadi YM, Lee JS, Scandiuzzi L, Ohaegbulam KC, Chinai JM, Zhao R, Yao Y, Mao Y, Sparano JA, Almo SC, Zang X.

Cell Rep. 2014 Nov 6;9(3):1089-98. doi: 10.1016/j.celrep.2014.09.053. Epub 2014 Oct 30.

26.

A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis.

Janakiram M, Sullivan M, Shcherba M, Guo S, Billett HH.

Thrombosis. 2013;2013:247913. doi: 10.1155/2013/247913. Epub 2013 Nov 19.

27.

T cell coinhibition and immunotherapy in human breast cancer.

Janakiram M, Abadi YM, Sparano JA, Zang X.

Discov Med. 2012 Oct;14(77):229-36. Review.

28.

Current and emerging therapies in primary myelofibrosis.

Ayyappan S, Janakiram M, Raghupathy R.

Cardiovasc Hematol Disord Drug Targets. 2012 Sep;12(1):6-20. Review.

PMID:
22746348
29.

Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma.

Janakiram M, Thirukonda VK, Sullivan M, Petrich AM.

Curr Treat Options Oncol. 2012 Mar;13(1):82-101. doi: 10.1007/s11864-011-0178-9. Epub 2012 Feb 2.

PMID:
22297843
30.

Acquired erythrocytosis upon treatment with infliximab for ankylosing spondylitis.

Antonelli M, Bupathi M, Janakiram M, Hergenroeder P, Khan MA.

J Rheumatol. 2011 Mar;38(3):581-3. doi: 10.3899/jrheum.101013. No abstract available.

PMID:
21362796
31.

An unusual cause of paraplegia.

Saravanan V, Janakiram M, Bankar RN, Kumar S, Nasar A.

Br J Hosp Med (Lond). 2006 Feb;67(2):97. No abstract available.

PMID:
16498919

Supplemental Content

Loading ...
Support Center